Showing results (1-10 of 784) with videos related to
Sort By:
Pageof 79
Critical Care (London, England)|August 12, 2009
Vasopressin and ischaemic heart disease: more than coronary vasoconstriction?Pierre Asfar, Peter RadermacherBest Practice & Research. Clinical Anaesthesiology|August 8, 2008
Impact of vasopressin analogues on the gut mucosal microcirculationPierre Asfar, Hendrik Bracht, Peter RadermacherCritical Care (London, England)|June 17, 2016
Cardiac surgery, a right target for hyperoxia?Julie Boisramé-Helms, Peter Radermacher, Pierre AsfarAnnals of Intensive Care|January 24, 2020
Vasopressin and its analogues in shock states: a reviewJulien Demiselle, Nicolas Fage, Peter Radermacher, et al.Minerva Anestesiologica|March 12, 2016
Mean arterial pressure target in patients with septic shockFrancois Beloncle, Peter Radermacher, Claude Guerin, et al.Critical Care (London, England)|January 8, 2008
Vasopressin in vasodilatory shock: hemodynamic stabilization at the cost of the liver and the kidney?Hendrik Bracht, Pierre Asfar, Peter Radermacher, et al.Annals of Intensive Care|October 31, 2018
Hemodynamic support in the early phase of septic shock: a review of challenges and unanswered questionsOlivier Lesur, Eugénie Delile, Pierre Asfar, et al.Current Opinion in Critical Care|December 19, 2009
The effects of vasopressin and its analogues on the liver and its disorders in the critically illPierre Asfar, Peter Radermacher, Paul Calès, et al.Critical Care (London, England)|August 17, 2016
Does hyperoxia enhance susceptibility to secondary pulmonary infection in the ICU?Benedikt Nußbaum, Peter Radermacher, Pierre Asfar, et al.International Journal of Molecular Sciences|February 25, 2023
Norepinephrine and Vasopressin in Hemorrhagic Shock: A Focus on Renal HemodynamicsNicolas Fage, Pierre Asfar, Peter Radermacher, et al.Pageof 79